NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.84 -0.79 (-0.96%) GOLD FUTURES
2,309.70 -48.00 (-2.04%) DOW
37,973.18 -412.91 (-1.08%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
LLY Jan 2025 250.000 put
| Previous close | 0.4600 |
| Open | 0.4600 |
| Bid | 0.0000 |
| Ask | 0.4200 |
| Strike | 250.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.4600 - 0.4600 |
| Contract range | N/A |
| Volume | |
| Open interest | 141 |
- Yahoo Finance Video
Eli Lilly stock jumps on weight-loss drug sales forecast
Shares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year revenue increase in a figure of $8.77 billion. Ultimately, this revenue print fell short of estimates ($8.92 billion). The pharmaceutical giant did, however, raise its annual sales forecast by $2 billion due to an insatiable demand for its GLP-1 weight-loss drugs Mounjaro and Zepbound. Yahoo Finance Health Reporter Anjalee Khemlani joins Catalysts to break down the report and what it means for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino
Yahoo FinanceHow expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
Investor's Business DailyStocks Weaken With Dow Sinking 300 Points; PayPal Breaks Out But Fades
The Dow Jones lost more than 300 points in the stock market today. PayPal Broke out but faded while Tesla stock sold off after a big gain.
